Erratum: Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment (Drugs (2013) 24 (677–689) DOI: 10.1097/CAD.0b013e328361b7ad);Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment

Anti-Cancer Drugs

Volumn 24, Issue 7, 2013, Pages 677-689

  Qiu, Zheng ^a   Hu, Jialiang ^a   Xu, Hanmei ^a   Wang, Wenjing ^a   Nie, Caihui ^a   Wang, Xiang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

angiogenesis; endostatin; matrix metalloproteinase

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; ENDOSTATIN; GELATINASE A; GELATINASE B; INHIBITOR2 PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR P2; MATRIX METALLOPROTEINASE INHIBITOR P4; NEUTROPHIL COLLAGENASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; EMBRYO MEMBRANE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TISSUE SECTION; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84879940870     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000869     Document Type: Erratum

References (38)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
2. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2:657-672.
3. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85:574-578.
4. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawler MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117:144-150.
5. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348:699-704.
6. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, et al. Expression of collagenase related metalloproteinase genes in human lung or head and neck tumors. Int J Cancer 1991; 48:550-556.
7. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA, et al. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serious tumors of the ovary. Am J Surg Pathol 1991; 16:500-507.
8. Gress TM, Muller-Pillasch F, Lerch MM, Freiss H, Buchler M, Alder G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-413.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
10. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 1996; 8:60-65.
11. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, et al. Angiogenesis as a target for tumor treatment. Oncology 1997; 54:177-184.
12. Mousa SA. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Fut 1998; 23:51-60.
13. Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85:683-693.
14. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-744.
15. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGFbeta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14:163-176.
16. Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 2008; 68:4606-4613.
17. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002; 277:21352-21360.
18. Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, et al. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res 2000; 6:3290-3296.
19. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
20. Wickström SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004; 279:20178-20185.
21. Xu HM, Yin R, Chen L, Siraj S, Huang X, Wang M, et al. An RGD-modified endostatin derived synthetic peptide shows antitumor activity in vivo. Bioconjug Chem 2008; 19:1980-1986.
22. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30:119-125.
23. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17:768-774.
24. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96:2673-2681.
25. Maragoudakis ME, Panoutsacopoulou M, Sarmonika M. Rate of basement membrane biosynthesis as an index to angiogenesis. Tissue Cell 1988; 20:531-539.
26. Qiu Z, Yan M, Li Q, Liu D, Van den Steen PE, Wang M, et al. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-a converting enzyme (TACE/ADAM-17). J Enzyme Inhib Med Chem 2012; 27:533-540.
27. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99:2735-2776.
28. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380.
29. Zhang X, Ren Y, Xu HM. Study on the in vitro antiangiogenic effect of an integrin antagonist HM-3. Chin J Pharm Biotech 2012; 19: 129-133.
30. Hu J, Dubois V, Chaltin P, Fiten P, Dillen C, Van den Steen PE, et al. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb Chem High Throughput Screen 2006; 9:599-611.
31. Yin R, Zheng H, Xi T, Xu HM. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide. Bioconjug Chem 2010; 21:1142-1147.
32. Pu CY, Xu HM, Hu JL, Zheng H, Huang XF, Zhang C, et al. RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis. Anticancer Drugs 2012; 23:788-802.
33. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81:761-766.
34. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4:85-92.
35. Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996; 2:1207-1214.
36. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56:2815-2822.
37. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392.
38. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 1999; 59:1231-1235.